Khan MS, Shahid I, Bennis A, Rakisheva A, Metra M, Butler J. Global epidemiology of heart failure. Nat Rev Cardiol. 2024;21(10):717–34.
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476–86.
Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488–504.
Tschope C, Kherad B, Klein O, Lipp A, Blaschke F, Gutterman D, et al. Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. Eur J Heart Fail. 2019;21(1):14–22.
Kimmoun A, Takagi K, Gall E, Ishihara S, Hammoum P, El Bèze N, et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades. Eur J Heart Fail. 2021;23(3):420–31.
Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res. 2021;128(10):1468–86.
Ibrahim NE, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123(5):614–29.
Schrader M, Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol. 2001;19(10 Suppl):S55-60.
Latosinska A, Frantzi M, Siwy J. Peptides as better biomarkers? Value, challenges, and potential solutions to facilitate implementation. Mass Spectrom Rev. 2024;43(6):1195–236.
Maes E, Oeyen E, Boonen K, Schildermans K, Mertens I, Pauwels P, et al. The challenges of peptidomics in complementing proteomics in a clinical context. Mass Spectrom Rev. 2019;38(3):253–64.
Hamamura K, Nonaka D, Ishikawa H, Banzai M, Yanagida M, Nojima M, et al. Simple quantitation for potential serum disease biomarker peptides, primarily identified by a peptidomics approach in the serum with hypertensive disorders of pregnancy. Ann Clin Biochem. 2016;53(Pt 1):85–96.
Zhuang B, Hu Y, Fan X, Li M, Zhu J, Liu H, et al. Peptidomic analysis of maternal serum to identify biomarker candidates for prenatal diagnosis of tetralogy of fallot. J Cell Biochem. 2018;119(1):468–77.
Bauza-Martinez J, Aletti F, Pinto BB, Ribas V, Odena MA, Diaz R, et al. Proteolysis in septic shock patients: plasma peptidomic patterns are associated with mortality. Br J Anaesth. 2018;121(5):1065–74.
Xu MY, Jia XF, Qu Y, Zheng RD, Yuan ZH, Weng HL, et al. Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B. J Transl Med. 2013;11:234.
Maddaloni E, Bolli GB, Frier BM, Little RR, Leslie RD, Pozzilli P, et al. C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective. Diabetes Obes Metab. 2022;24(10):1912–26.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263–421.
Radosavljevic-Radovanovic M, Radovanovic N, Vasiljevic Z, Marinkovic J, Mitrovic P, Mrdovic I, Stankovic S, Kruzliak P, Beleslin B, Uscumlic A, et al. Usefulness of NT-proBNP in the Follow-Up of patients after myocardial infarction. J Med Biochem. 2016;35(2):158–65.
Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43(4):635–41.
Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, Committee ASA. Investigators: admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943–50.
Pastormerlo LE, Maffei S, Latta DD, Chubuchny V, Susini C, Berti S, Prontera C, Storti S, Passino C, Pasanisi E, et al. N-terminal fragment of B-type natriuretic peptide predicts coexisting subclinical heart and vessel disease. J Cardiovasc Med (Hagerstown). 2017;18(10):750–7.
Liu CY, Heckbert SR, Lai S, Ambale-Venkatesh B, Ostovaneh MR, McClelland RL, et al. Association of elevated NT-proBNP with myocardial fibrosis in the Multi-Ethnic study of atherosclerosis (MESA). J Am Coll Cardiol. 2017;70(25):3102–9.
Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, Martínez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, et al. Serum carboxy-terminal propeptide of Procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101(14):1729–35.
Raafs AG, Verdonschot JAJ, Henkens M, Adriaans BP, Wang P, Derks K, Abdul Hamid MA, Knackstedt C, van Empel VPM, Diez J, et al. The combination of carboxy-terminal propeptide of Procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy – A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. Eur J Heart Fail. 2021;23(6):933–44.
Duprez DA, Gross MD, Kizer JR, Ix JH, Hundley WG, Jacobs DR Jr. Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction: MESA (multi-ethnic study of atherosclerosis). J Am Heart Assoc. 2018;7(5):e007885.
Ma K, Yang J, Shao Y, Li P, Guo H, Wu J, et al. Therapeutic and prognostic significance of arachidonic acid in heart failure. Circ Res. 2022;130(7):1056–71.
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.
Minkiewicz P, Iwaniak A, Darewicz M. BIOPEP-UWM database of bioactive peptides: current opportunities. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20235978.
Foreman RE, George AL, Reimann F, Gribble FM, Kay RG. Peptidomics: a review of clinical applications and methodologies. J Proteome Res. 2021;20(8):3782–97.
Doellinger J, Schneider A, Hoeller M, Lasch P. Sample preparation by easy extraction and digestion (SPEED) – a universal, rapid, and detergent-free protocol for proteomics based on acid extraction. Mol Cell Proteomics. 2020;19(1):209–22.
Hellinger R, Sigurdsson A, Wu W, Romanova EV, Li L, Sweedler JV, Süssmuth RD. Gruber CW: peptidomics. Nat Rev Methods Primers. 2023;3:25.
Luo S, Hu D, Wang M, Zipfel PF, Hu Y. Complement in hemolysis- and thrombosis- related diseases. Front Immunol. 2020;11:1212.
Egerstedt A, Berntsson J, Smith ML, Gidlof O, Nilsson R, Benson M, Wells QS, Celik S, Lejonberg C, Farrell L, et al. Profiling of the plasma proteome across different stages of human heart failure. Nat Commun. 2019;10(1):5830.
Simurda T, Brunclikova M, Asselta R, Caccia S, Zolkova J, Kolkova Z, et al. Genetic variants in the FGB and FGG genes mapping in the beta and gamma nodules of the fibrinogen molecule in congenital quantitative fibrinogen disorders associated with a thrombotic phenotype. Int J Mol Sci. 2020;21(13):4616.
Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011;25(6):239–45.
Surma S, Banach M. Fibrinogen and atherosclerotic cardiovascular diseases-review of the literature and clinical studies. Int J Mol Sci. 2021;23(1):193.
Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133(6):511–20.
Sánchez-Cortés J, Mrksich M. The platelet integrin alphaIIbbeta3 binds to the RGD and AGD motifs in fibrinogen. Chem Biol. 2009;16(9):990–1000.
Lu PP, Liu JT, Liu N, Guo F, Ji YY, Pang X. Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS. Life Sci. 2011;88(19–20):839–45.
Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, González-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850.
Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiol (Oxf). 2010;198(1):1–13.
Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, et al. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood. 2004;103(5):1728–34.
Lassé M, Pilbrow AP, Kleffmann T, Andersson Överström E, von Zychlinski A, Frampton CMA, et al. Fibrinogen and hemoglobin predict near future cardiovascular events in asymptomatic individuals. Sci Rep. 2021;11(1):4605.
Zhu M, Wei J, Li Y, Wang Y, Ren J, Li B, et al. Efficacy and mechanism of Buyang Huanwu Decoction in patients with ischemic heart failure: a randomized, double-blind, placebo-controlled trial combined with proteomic analysis. Front Pharmacol. 2022;13:831208.
Wang J, Zhang Y, Liu YM, Yang XC, Chen YY, Wu GJ, et al. Uncovering the protective mechanism of Huoxue anxin recipe against coronary heart disease by network analysis and experimental validation. Biomed Pharmacother. 2020;121:109655.
Buchan TA, Ching C, Foroutan F, Malik A, Daza JF, Hing NNF, et al. Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis. Heart Fail Rev. 2022;27(2):645–54.